| pubmed-article:11697505 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C1511790 | lld:lifeskim |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C1511695 | lld:lifeskim |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C0599161 | lld:lifeskim |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C1708632 | lld:lifeskim |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C0182400 | lld:lifeskim |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:11697505 | lifeskim:mentions | umls-concept:C1522485 | lld:lifeskim |
| pubmed-article:11697505 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11697505 | pubmed:dateCreated | 2001-11-7 | lld:pubmed |
| pubmed-article:11697505 | pubmed:abstractText | The persistence of the AML1-ETO rearrangement performed by reverse transcription polymerase chain reaction (RT-PCR) has been reported in acute myeloid leukemia (AML) patients in long-term complete remission (CR). This persistence, which is not associated with hematological relapse, limits the clinical use of qualitative RT-PCR. Here, we present a new quantitative real-time PCR method to detect AML1-ETO rearrangement using fluorescently labeled probes. Quantitative detection of AML1-ETO was performed in capillary tubes using two fluorescently labeled probes in the LightCycler equipment. The reliability of the method was checked in twenty-two bone marrow samples and one apheresis sample from eight patients with t(8;21) collected at diagnosis and during follow-up assessment. The regression coefficients obtained for standard curves of AML1-ETO and AML were all greater than 0.98. The sensitivity attained allowed the detection of rearrangements at a dilution of 10(-5) Kasumi-1 cDNA. The intra-assay coefficient of variation was 4% for AML1-ETO, and 7% for AML. The inter-assay coefficient of variation was 19% for AML1-ETO and 12% for AML. A log reduction from two to four in the AML1-ETO/AML ratio was evident after CR. The study of the method and first results obtained in patient samples support that quantitative real-time PCR with hybridization probes is a new reliable and sensitive method to monitor minimal residual disease in AML patients. Moreover, the fluorescent probes with the Light-Cycler technology offer the advantage of a rapid detection. | lld:pubmed |
| pubmed-article:11697505 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11697505 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11697505 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11697505 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:11697505 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:BrunetSS | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:BoluferPP | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:SanzM AMA | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:FernándezPP | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:RivasCC | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:MorenoII | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:MartínGG | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:NomdedeuJJ | lld:pubmed |
| pubmed-article:11697505 | pubmed:author | pubmed-author:BarragánEE | lld:pubmed |
| pubmed-article:11697505 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11697505 | pubmed:volume | 42 | lld:pubmed |
| pubmed-article:11697505 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11697505 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11697505 | pubmed:pagination | 747-56 | lld:pubmed |
| pubmed-article:11697505 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:meshHeading | pubmed-meshheading:11697505... | lld:pubmed |
| pubmed-article:11697505 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11697505 | pubmed:articleTitle | Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes. | lld:pubmed |
| pubmed-article:11697505 | pubmed:affiliation | Department of Clinical Pathology, Hospital Universitario La Fe Valencia, Spain. | lld:pubmed |
| pubmed-article:11697505 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11697505 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11697505 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11697505 | lld:pubmed |
